Vivet Therapeutics is focused on developing innovative gene therapies for rare inherited liver metabolic disorders, with a particular emphasis on conditions such as Wilson disease and cerebrotendinous xanthomatosis (CTX). Their lead program, VTX-801, is an adeno-associated virus (AAV)-based gene therapy designed to deliver a corrective version of the ATP7B gene, which is crucial for copper metabolism in Wilson disease patients. The therapy is currently undergoing clinical evaluation in a Phase 1/2 trial, demonstrating promising safety and early pharmacodynamic changes. Additionally, Vivet is advancing other AAV-based therapies, including VTX-802 and VTX-803 for Progressive Familial Intrahepatic Cholestasis, and VTX-804 for Citrullinemia Type 1, all of which aim to address specific genetic deficiencies by delivering optimized gene constructs to the liver.

The company is also exploring advanced technologies such as VTX-PSM, which aims to ensure sustained expression of therapeutic genes without integrating into the host genome, and VTX-PID, which targets the depletion of neutralizing antibodies to enhance the efficacy of AAV gene therapies. These innovative approaches are designed to overcome existing limitations in gene therapy, particularly for patients who may have developed antibodies against AAV vectors due to previous treatments or infections. By leveraging these technologies, Vivet Therapeutics aims to provide long-lasting and effective treatments for patients suffering from genetic disorders, ultimately improving their quality of life and addressing significant unmet medical needs in the field.

France

Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. Vivet Therapeutics is focused on optimizing gene therapy through collaborating with the Fundacion para la Investigacion Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression. 

Vivet Therapeutics

Company Details